AAAAAA

   
Results: 1-14 |
Results: 14
Numerical selection of optimal tumor imaging agents with application to engineered antibodies
Authors: Williams, LE Wu, AM Yazaki, PJ Liu, A Raubitschek, AA Shively, JE Wong, JYC
Citation: Le. Williams et al., Numerical selection of optimal tumor imaging agents with application to engineered antibodies, CANC BIO R, 16(1), 2001, pp. 25-35
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments
Authors: Yazaki, PJ Wu, AM Tsai, SW Williams, LE Ikle, DN Wong, JYC Shively, JE Raubitschek, AA
Citation: Pj. Yazaki et al., Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments, BIOCONJ CHE, 12(2), 2001, pp. 220-228
Mammalian expression and hollow fiber bioreactor production of recombinantanti-CEA diabody and minibody for clinical applications
Authors: Yazaki, PJ Shively, L Clark, C Cheung, CW Le, W Szpikowska, B Shively, JE Raubitschek, AA Wu, AM
Citation: Pj. Yazaki et al., Mammalian expression and hollow fiber bioreactor production of recombinantanti-CEA diabody and minibody for clinical applications, J IMMUNOL M, 253(1-2), 2001, pp. 195-208
A phase I radioimmunotherapy trial evaluating (90)yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84,66 in patients with metastatic CEA-producing malignancies
Authors: Wong, JYC Chu, DZ Yamauchi, DM Williams, LE Liu, A Wilczynski, S Wu, AM Shively, JE Doroshow, JH Raubitschek, AA
Citation: Jyc. Wong et al., A phase I radioimmunotherapy trial evaluating (90)yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84,66 in patients with metastatic CEA-producing malignancies, CLIN CANC R, 6(10), 2000, pp. 3855-3863
Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5
Authors: Tsai, SW Sun, YY Williams, LE Raubitschek, AA Wu, AM Shively, JE
Citation: Sw. Tsai et al., Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5, BIOCONJ CHE, 11(3), 2000, pp. 327-334
Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy
Authors: Wong, JYC Wang, JY Liu, AL Odom-Maryon, T Shively, JE Raubitschek, AA Williams, LE
Citation: Jyc. Wong et al., Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy, INT J RAD O, 46(3), 2000, pp. 599-607
Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies
Authors: Williams, LE Liu, A Wu, AM Yazaki, PJ Yamauchi, DM Lopatin, G Raubitschek, AA Wong, JYC
Citation: Le. Williams et al., Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies, MED PHYS, 27(5), 2000, pp. 988-994
High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment
Authors: Wu, AM Yazaki, PJ Tsai, SW Nguyen, K Anderson, AL McCarthy, DW Welch, MJ Shively, JE Williams, LE Raubitschek, AA Wong, JYC Toyokuni, T Phelps, ME Gambhir, SS
Citation: Am. Wu et al., High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment, P NAS US, 97(15), 2000, pp. 8495-8500
Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging
Authors: Wu, AM Williams, LE Zieran, L Padma, A Sherman, M Bebb, GG Odom-Maryon, T Wong, JYC Shively, JE Raubitschek, AA
Citation: Am. Wu et al., Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging, TUMOR TARG, 4(1), 1999, pp. 47-58
A method for patient-specific absorbed dose estimation for internal beta emitters
Authors: Williams, LE Liu, A Raubitschek, AA Wong, JYC
Citation: Le. Williams et al., A method for patient-specific absorbed dose estimation for internal beta emitters, CLIN CANC R, 5(10), 1999, pp. 3015S-3019S
Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
Authors: Wong, JYC Somlo, G Odom-Maryon, T Williams, LE Liu, A Yamauchi, D Wu, AM Yazaki, P Wilczynski, S Shively, JE Forman, S Doroshow, JH Raubitschek, AA
Citation: Jyc. Wong et al., Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer, CLIN CANC R, 5(10), 1999, pp. 3224S-3231S
A radionuclide therapy treatment planning and dose estimation system
Authors: Liu, A Williams, LE Lopatin, G Yamauchi, DM Wong, JYC Raubitschek, AA
Citation: A. Liu et al., A radionuclide therapy treatment planning and dose estimation system, J NUCL MED, 40(7), 1999, pp. 1151-1153
Intrapatient consistency of imaging biodistributions and their applicationto predicting therapeutic doses in a phase I clinical study of Y-90-based radioimmunotherapy
Authors: Clarke, KG Odom-Maryon, TL Williams, LE Liu, A Lopatin, G Chou, J Farino, GM Raubitschek, AA Wong, JYC
Citation: Kg. Clarke et al., Intrapatient consistency of imaging biodistributions and their applicationto predicting therapeutic doses in a phase I clinical study of Y-90-based radioimmunotherapy, MED PHYS, 26(5), 1999, pp. 799-809
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients
Authors: Wong, JYC Chu, DZJ Yamauchi, D Odom-Maryon, TL Williams, LE Liu, A Esteban, JM Wu, AM Primus, FJ Beatty, JD Shively, JE Raubitschek, AA
Citation: Jyc. Wong et al., Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients, J NUCL MED, 39(12), 1998, pp. 2097-2104
Risultati: 1-14 |